Skip to main content
OpenTrials
Completed

NCT Number: NCT00589511

Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study

The objective of this multisite study is to evaluate the performance of the Nucleus Freedom cochlear implant system in a large population of sequentially implanted pediatric subjects.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The proposed study will include 50 pediatric subjects ages 1 year to 17 years, 11 months of age, implanted at up to 5 sites in the United States and Canada. The estimated duration of this multisite study is 18 to 24 months. The duration of individual subject participation is not to exceed 12 months.

The study will be conducted as a within-subject repeated measures experiment (in which each subject serves as his or her own control) in order to accommodate the heterogeneity that is well known to characterize hearing-impaired populations

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1 year to 17 years, 11 months of age.
  • Bilateral severe to profound sensorineural hearing loss for those 1 to 2 years of age. Severe hearing loss for those 2 years of age and older.
  • Limited benefit from bilateral hearing aids. Limited benefit is defined as a lack of progress in the development of simple auditory skills in conjunction with appropriate amplification and intensive aural rehabilitation over a 3 to 6 month period.
  • For younger children, unable to take speech perception tests due to age-related cognitive and linguistic limitations, limited benefit will be quantified using the Infant Toddler Meaningful Auditory Integration Scale (IT-MAIS)1 or Meaningful Auditory Integration Scale (MAIS)1.
  • For older children, capable of speech perception tasks, limited benefit is defined as £ 30% on the recorded open-set Multisyllabic Lexical Neighborhood Test (MLNT)2 or Lexical Neighborhood Test (LNT) 2, depending on the child's cognitive and linguistic skills.
  • English spoken as a primary language.
  • Willingness to participate in and to comply with all requirements of the protocol.

Exclusion criteria

  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array, as confirmed by medical examination and tests including MRI.
  • Signs of retrocochlear or central origin to hearing impairment as confirmed by medical examination and tests including MRI.
  • Medical or psychological conditions that would contraindicate undergoing surgery (e.g., active middle ear infections, tympanic membrane perforation).
  • Additional handicaps that would prevent or restrict participation in the evaluations.
  • Unrealistic expectations on the part of the subject or subject's parents/guardians, regarding the possible benefits, risks and limitations that are inherent to the surgical procedure and prosthetic device.
  • Unwillingness or inability of the candidate or candidate's parents/guardians to comply with all study requirements.

Treatment and study plan

Primary outcomes

  1. IT-MAIS

    Time frame: 12 Months

  2. MAIS

    Time frame: 12 Months

  3. MLNT

    Time frame: 12 Months

  4. LNT

    Time frame: 12 Months

Sponsors and collaborators

Lead sponsor

Cochlear

Industry

Registry information

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Jan 9, 2008
Registry last updated
Aug 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.